NCT03207347View on ClinicalTrials.gov

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
MesotheliomaUveal MelanomaRenal Cell CarcinomaCholangiocarcinoma
Interventions
DRUG

Niraparib

Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.

Trial Locations (3)

32610

University of Florida, Gainesville

32806

Orlando Health UF Health Cancer Center, Orlando

33136

University of Miami, Miami

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Florida

OTHER

NCT03207347 - A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Biotech Hunter | Biotech Hunter